STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

• Published in: Therapeutic advances in medical oncology Vol. 10; p. 1758835918763744
• Main Authors: Attili, Ilaria, Karachaliou, Niki, Bonanno, Laura, Berenguer, Jordi, Bracht, Jillian, Codony-Servat, Jordi, Codony-Servat, Carles, Ito, Masaoki, Rosell, Rafael
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2018; Sage Publications Ltd; SAGE Publishing
• Subjects: Biomarkers; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; Non-small cell lung carcinoma; Oncogenes; Small cell lung carcinoma; Stat3 protein; Tumor cells; Tumors; lung cancer; PD-L1; biomarkers; immunotherapy; STAT3
• ISSN: 1758-8340; 1758-8359; 1758-8359
• DOI: 10.1177/1758835918763744

Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.